![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...
![](/fileadmin/_processed_/csm_NCI-radiopharma_21ffe1bccf.png)
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek....
![](/fileadmin/_processed_/csm_SBA__c__Elvin_YilmazElvin_Yilmaz.jpg__a5edabbb67.jpg)
Swiss Biotech Report reporting record turnover
The Swiss Biotech Report 2024 commissioned by the Swiss Biotech Association and co-published with EY on the occasion of the Swiss Biotech Day...
![](/fileadmin/_processed_/csm_Margrete_Vestager_cutting_red_tape._c__21st_Century_A_S_adbd43f540.jpg)
Danish 21st.BIO A/S opens multipurpose production plant
Today, EU Executive Vice-President Margrete Vestager launched a multi-purpose pilot production facility in Copenhagen, with which 21st.BIO A/S aims...
![](/fileadmin/_processed_/csm_Neurosense-pipeline_38841e73e1.png)
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
![](/fileadmin/_processed_/csm_drugs_pills_-web_4e35a70ff4.jpg)
Ten drug recommendations by EMA
The committee recommended end of June granting a marketing authorisation for Balversa (erdafitinib), for the treatment of adult...
![](/fileadmin/_processed_/csm_Apeiron_Board_148036936f.png)
Ligand Pharma to acquire Apeiron Biologics
As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics...